Skip to main content

Table 1 Characteristics of eligible studies for survival analysis

From: Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis

Author Year Country Sample size Percent of IDC (%) Cut-offa Follow-up Protein Survival outcome HR data Survival analysis NOS
Talvensaari-Mattila [51] 1998 Finland 169 82 P > 0% 92 months MMP2 OS Rep U 8
Talvensaari-Mattila [50] 1999 Finland 108 96 P > 0% 2 years MMP2 RFS Est U 8
Talvensaari-Mattila [49] 2001 Finland 100 79 P > 0% 44 months MMP2 OS, RFS Est U 7
Scorilas 2011 Greece 210 75 HSCORE> 175 62 months MMP9 OS, RFS Rep U, M 7
Djonov [48] 2002 Switzerland 75 61 SI ≥ 1 NR MMP2 OS, DFS Rep M 6
Hirvonen [47] 2003 Finland 137 NR P > 0% 10 years MMP2 RFS Est U 6
Fan [45] 2003 China 66 86 SI ≥ 1 30.5 months MMP2, MMP9 OS Rep M 6
Talvensaari-Mattila [44] 2003 Finland 453 75 P > 0% 60–150 months MMP2 OS Rep M 8
Li [19] 2004 China 270 90 P > 0% 61 months MMP2, MMP9 OS, RFS Rep U, M 6
Pellikainen [58] 2004 Finland 415 64 P > 85%b 55 months MMP9 RFS Rep M 7
Rahko [23] 2004 Finland 168 75 P > 1% 7–111 months MMP9 OS, DFS Rep U 7
Ban [52] 2004 China 60 100 SI ≥ 3 > 5 years MMP2 OS Est U 7
Zhou [42] 2005 China 112 84 P > 5% 48 months MMP2 OS Rep M 7
Zhang [38] 2008 China 263 100 SI ≥ 6 92.1 months MMP2, MMP9 OS Rep U 6
Zhao [53] 2008 China 71 93 P > 10% 54.94 months MMP9 OS Est U 6
Sullu [22] 2011 Turkey 140 100 SI ≥ 5 63.2 months MMP9 OS, DFS Est U 8
Ranogajec [37] 2012 Croatia 138 59 SI ≥ 2 5 years MMP2 OS Est U 7
Fernandez-Guinea [21] 2013 Spain 97 100 SI > 5 years MMP2, MMP9 RFS Rep U, M 6
Zhao [18] 2013 China 127 NR SI ≥ 6 NR MMP9 OS Rep M 6
Liu [17] 2013 China 189 89 P > 10% NR MMP9 OS Rep U, M 8
Zeng [36] 2013 China 253 NR P > 20% 15 years MMP9 OS, DFS Rep U, M 8
Merdad [20] 2014 Saudi Arabia 45 84 SI ≥ 2 52.1 months MMP9 OS Rep U 7
Puzovic [35] 2014 Croatia 121 100 SI 80.6 months MMP2, MMP9 OS, DFS Rep U 7
Min [32] 2014 Korea 177 100 SI ≥ 1, SI ≥ 5 NR MMP2, MMP9 OS Rep M 7
Yousef [30] 2014 Canada 300 NR SI ≥ 5 NR MMP9 RFS Est U 6
Bottino [59] 2014 Brazil 60 1 MOD> 191 NR MMP9 OS Rep U 7
Huang [55] 2014 China 147 86 P > 10% 45.6 months MMP9 OS, DFS Rep U, M 6
Ramos [29] 2016 Brazil 44 77 P > 10% NR MMP2 OS, DFS Est U 7
Li [16] 2017 China 80 NR P > 25% NR MMP2, MMP9 OS Est U 7
Yang [28] 2018 Korea 173 100 SI ≥ 2 NR MMP9 OS, DFS Rep U, M 8
Zhang [56] 2019 China 127 NR SI ≥ 6 NR MMP9 OS Rep M 7
  1. aCut-off for overexpression of matrix metalloproteinases in tumor cells by immunohistochemistry
  2. bMedian value
  3. IDC infiltrating ductal carcinoma, P percentage of stained cells, SI staining index considering both percentage and intensity of staining, OS overall survival, DFS disease-free survival, RFS recurrence-free survival, Rep reported in the text, Est estimated from survival curve, U univariate analysis, M multivariate analysis, NR not reported, MOD mean optical density